The downregulation of CPT‐1 activity caused by TDGA canceled the decrease in serum ALT levels as well as fat accumulation by the low‐dose of α‐Toc treatment although TDGA alone did not worse HF‐induced hepatic accumulation and induce hepatic steatosis in this study, strengthening the findings that a low‐dose of α‐Toc improves NAFLD through the regulation of CPT‐1 activity. Here, CPT1A is linked to metabolic dysfunction-associated steatotic liver disease.